Recombinant human CD39 protein (Active) (His tag C-Terminus)
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant human CD39 protein (Active) (His tag C-Terminus) is a Human Fragment protein, in the 38 to 478 aa range, expressed in HEK 293 cells, with >90%, suitable for SDS-PAGE, FuncS.
View Alternative Names
CD39, ENTPD1, Ectonucleoside triphosphate diphosphohydrolase 1, ATP diphosphohydrolase, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen, Nucleoside triphosphate diphosphohydrolase 1, ATP-DPH, ATPDase, Ecto-ATPDase 1, Ecto-ATPase 1, NTPDase1
- FuncS
Unknown
Functional Studies - Recombinant human CD39 protein (Active) (His tag C-Terminus) (AB271430)
Functional analysis of ab271430.
Specific activity >3000 pmol/min/μg.
Colorimetric ATP hydrolysis assay.
- SDS-PAGE
Unknown
SDS-PAGE - Recombinant human CD39 protein (Active) (His tag C-Terminus) (AB271430)
SDS-PAGE analysis of ab271430.
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Specifications
Form
Liquid
General info
Function
Catalyzes the hydrolysis of both di- and triphosphate nucleotides (NDPs and NTPs) and hydrolyze NTPs to nucleotide monophosphates (NMPs) in two distinct successive phosphate-releasing steps, with NDPs as intermediates and participates in the regulation of extracellular levels of nucleotides (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed : 8955160, PubMed : 8996251).
Sequence similarities
Belongs to the GDA1/CD39 NTPase family.
Post-translational modifications
N-glycosylated.. The N-terminus is blocked.. Palmitoylated on Cys-13; which is required for caveola targeting.
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com